| Authors: |
Buchbinder E; Dana-Farber Cancer Institute, Boston, Massachusetts, USA elizabeth_buchbinder@dfci.harvard.edu., Lotze MT; University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Margolin KA; Medical Oncology, City of Hope National Medical Center, Duarte, California, USA., Amaria R; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sarnaik A; H Lee Moffitt Canc Ctr, Tampa, Florida, USA., Seery V; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Eroglu Z; Moffitt Cancer Center, Tampa, Florida, USA., Khaddour K; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Betof Warner A; Stanford University School of Medicine, Stanford, California, USA., Kluger HM; Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA., Sznol M; Yale Cancer Center, Yale University, New Haven, Connecticut, USA., Atkins MB; Oncology, Georgetown University, Washington, District of Columbia, USA., Mcdermott DF; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Silk AW; Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA. |
